PPARG and glioblastoma: Overexpression of PPARγ is also a hallmark of GBM cells [33] and it has been documented that the PPARγ agonists thiazolidinediones and Fmoc-L-Leucine inhibit growth, proliferation, and induce apoptosis in various human glioblastoma cells in vivo, and thus may be regarded as a potential agents for GBM therapy [34,35,36,37,38,39].